Obermeier Katharina Theresa, Smolka Wenko, Palla Benjamin, Kraus Moritz, Steybe David, Hartung Jens Tobias, Fegg Florian Nepomuk, Hildebrandt Tim, Dewenter Ina, Callahan Nicholas, Poxleitner Philipp, Otto Sven
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Germany.
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Germany.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2025 Jan;139(1):11-19. doi: 10.1016/j.oooo.2024.07.008. Epub 2024 Aug 9.
Patients exposed to a combination of antiresorptive medication and radiotherapy of the head and neck area developing necrosis of the jaw in the course of treatment are extremely rare. Therefore, the aim of this study was to identify the outcome and complications in this highly vulnerable patient cohort.
Seventeen patients who received both antiresorptive treatment and radiotherapy (medication-related osteonecrosis of the jaw/osteoradionecrosis = the [MRONJ/ORN] group) in the head and neck area were enrolled in this study. Included patients were treated in our department between 2005 and 2022. Four hundred twenty-four patients with MRONJ (the MRONJ group) and 138 patients with ORN of the jaw were enrolled as two control groups (the ORN group). Demographic data, lesion localization, date of primary diagnosis, clinical symptoms, type of therapy (surgical or non-surgical), details on antiresorptive treatment, outcome, and complications were recorded.
Pathological fractures, continuity resection, and recurrence appear more often in patients who receive a combination of antiresorptive treatment and radiotherapy in the head and neck area compared with patients undergoing only one of these treatments. There was a statistically significant difference (P < .001) between the MRONJ/ORN group and the MRONJ group and the MRONJ/ORN group and the ORN group considering recurrence, fracture, and continuity resection. Patients with ORN combined with MRONJ have a 4-times higher risk for developing recurrence compared with patients with MRONJ and a 1.5-times higher risk for recurrence compared with patients with ORN. Jaw fracture and continuity resection appear more often in patients with MRONJ/ORN.
Patients under antiresorptive therapy in combination with radiation therapy in the head and neck area have a higher risk for developing complications in case of osteonecrosis of the jaw. Therefore, a strict follow-up care schedule is highly recommended.
在治疗过程中,同时接受抗吸收药物和头颈部放疗而发生颌骨坏死的患者极为罕见。因此,本研究的目的是确定这一高度脆弱患者群体的治疗结果和并发症。
本研究纳入了17例在头颈部同时接受抗吸收治疗和放疗(药物相关性颌骨坏死/放射性骨坏死 = [MRONJ/ORN]组)的患者。纳入的患者于2005年至2022年在我们科室接受治疗。将424例MRONJ患者(MRONJ组)和138例颌骨ORN患者作为两个对照组(ORN组)。记录人口统计学数据、病变部位、初次诊断日期、临床症状、治疗类型(手术或非手术)、抗吸收治疗细节、治疗结果和并发症。
与仅接受其中一种治疗的患者相比,在头颈部同时接受抗吸收治疗和放疗的患者中,病理性骨折、连续性切除和复发更为常见。在复发、骨折和连续性切除方面,MRONJ/ORN组与MRONJ组以及MRONJ/ORN组与ORN组之间存在统计学显著差异(P <.001)。与MRONJ患者相比,ORN合并MRONJ的患者发生复发的风险高4倍,与ORN患者相比,复发风险高1.5倍。颌骨骨折和连续性切除在MRONJ/ORN患者中更为常见。
头颈部接受抗吸收治疗联合放疗的患者在发生颌骨坏死时出现并发症的风险更高。因此,强烈建议制定严格的随访护理计划。